RPL17 and neoplasm: Antitumor activity will be defined by response improvement with the addition of GEN-009 to nivolumab compared with nivolumab monotherapy as described in (Table 1).Part C will treat patients who have the above-noted tumor types and have previously received standard therapy that included a PD-1 or PD-L1 inhibitor with GEN-009 as a monotherapy.